Cagrilintide
Peptide therapy: benefits, side effects, cost and protocols
C194H312N54O59S2
Cagrilintide is a long-acting analogue of amylin being tested for obesity and type 2 diabetes treatment, both alone and in combination with semaglutide (CagriSema) for enhanced weight loss efficacy.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
- Evidence
- Strong Evidence
Who it's for
Who Cagrilintide is usually considered for
- Appetite regulation
- Weight management research
- Glycemic control
Mechanism
How Cagrilintide works
Amylin receptor agonist that may influence satiety signaling, slow gastric emptying, and reduce glucagon secretion.
Evidence
Key studies
109 papers on PubMed / 66 human trials
- 01
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1
- 02
Verma S, Böttcher M, Brown P et al
Hypertension / Phase 3
CagriSema reduced systolic BP by 10.9 mmHg versus 2.8 mmHg with placebo at week 68.
- 03
CagriSema reduced systolic BP by 10.9 mmHg versus 2.8 mmHg with placebo at week 68
- 04
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
- 05
Garvey WT, Blüher M, Osorto Contreras CK et al
N Engl J Med / Phase 3
Cagrilintide-semaglutide achieved 20.4% weight loss vs 3.0% placebo in adults with overweight/obesity.
- 06
Cagrilintide-semaglutide achieved 20.4% weight loss vs 3.0% placebo in adults with overweight/obesity
- 07
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- 08
Davies MJ, Bajaj HS, Broholm C et al
N Engl J Med / Phase 3
Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% placebo in type 2 diabetes.
- 09
Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% placebo in type 2 diabetes
- 10
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Compound
Cagrilintide compound data
- Formula
- C194H312N54O59S2
- Mol. weight
- 4409 g/mol
- PubChem CID
- 171397054 ↗
- IUPAC
- 20-[[(1S)-4-[[(1S)-5-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(1S)-2-[[(1S,2R)-1-[[(1S)-4-amino-1-[[(1S)-1-[[(1R)-1-[[(1R)-2-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-3-amino-1-[[(1S)-3-amino-1-[[(1S)-2-[[2-[(2S)-2-[[(1S,2S)-1-[[(1R)-1-[(2R)-2-[(2R)-2-[[(1R,2S)-1-[[(1R)-3-amino-1-[[(1R)-1-[[2-[[(1R)-2-[[(1R)-3-amino-1-[[(1R,2S)-1-[(2R)-2-carbamoylpyrrolidine-1-carbonyl]-2-hydroxy-propyl]carbamoyl]-3-oxo-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-2-methyl-propyl]carbamoyl]-3-oxo-propyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-3-methyl-butyl]carbamoyl]-2-methyl-butyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-ethyl]amino]-1-benzyl-2-oxo-ethyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-oxo-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]amino]-1-benzyl-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-4-oxo-butyl]carbamoyl]-2-hydroxy-propyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-16-(2-amino-2-oxo-ethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]carbamoyl]pentyl]amino]-1-carboxy-4-oxo-butyl]amino]-20-oxo-icosanoic acid
FAQ
Cagrilintide questions
What is CAGRILINTIDE?
Cagrilintide is a long-acting amylin analog researched for weight management. It works differently from GLP-1 agonists and is often studied in combination with other peptides.
How does CAGRILINTIDE work?
Amylin receptor agonist that may influence satiety signaling, slow gastric emptying, and reduce glucagon secretion.
Is CAGRILINTIDE legal to buy?
CAGRILINTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy CAGRILINTIDE?
CAGRILINTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does CAGRILINTIDE belong to?
CAGRILINTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of CAGRILINTIDE?
CAGRILINTIDE has been studied for: Appetite regulation, Weight management research, Glycemic control. Amylin analog; often researched in combination protocols.
News
Cagrilintide in the news
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors - Nature
Nature / 19 months ago
Co-formulation of Semaglutide and Cagrilintide Shows Promise Against Diabetes and Obesity - Pharmacy Times
Pharmacy Times / 24 months ago
CagriSema for Weight Loss: How Does It Compare to Other GLP-1s? - GoodRx
GoodRx / 17 months ago
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial - The Lancet
The Lancet / 61 months ago
Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials - 2 Minute Medicine
2 Minute Medicine / 67 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Cagrilintide?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.